Page last updated: 2024-08-23

bromocriptine and dihydroergocryptine

bromocriptine has been researched along with dihydroergocryptine in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dantzig, AH; Ekins, S; Kim, RB; Lan, LB; Leake, BF; Schuetz, EG; Schuetz, JD; Shepard, RL; Wikel, JH; Winter, MA; Wrighton, SA; Yasuda, K1
Furuya, K; Lan, LB; Sanglard, D; Schuetz, EG; Schuetz, JD; Yasuda, K1
Goetz, CG; Poewe, W; Rascol, O; Sampaio, C1
Lee, MR1
Bernard, N; Descotes, J; Gillet, A; Gouraud, A; Mirkou, A; Suchovsky, D; Vial, T1

Reviews

1 review(s) available for bromocriptine and dihydroergocryptine

ArticleYear
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:5

    Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone

2005

Other Studies

4 other study(ies) available for bromocriptine and dihydroergocryptine

ArticleYear
Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
    Molecular pharmacology, 2002, Volume: 61, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Ergonovine; Fluoxetine; Humans; Models, Molecular; Oxytocics; Protein Conformation; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship; Swine; Transfection; Vinblastine

2002
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:1

    Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dihydroergocryptine; Drug Interactions; Enzyme Inhibitors; Fluconazole; Humans; Mice; Mice, Knockout; Microsomes, Liver; Oxidoreductases, N-Demethylating; Recombinant Proteins; Reserpine; Swine; Tissue Distribution; Transfection; Vinblastine

2002
The history of ergot of rye (Claviceps purpurea) III: 1940-80.
    The journal of the Royal College of Physicians of Edinburgh, 2010, Volume: 40, Issue:1

    Topics: Bromocriptine; Claviceps; Dihydroergocryptine; Ergot Alkaloids; History, 20th Century; Humans; Lysergic Acid Diethylamide; Parkinson Disease; Prolactinoma; Receptors, Dopamine; Schizophrenia; Scotland; Secale

2010
[Prescription of ergot derivatives for lactation inhibition in France: Current practices].
    Journal de gynecologie, obstetrique et biologie de la reproduction, 2012, Volume: 41, Issue:2

    Topics: Bromocriptine; Cabergoline; Dihydroergocryptine; Dopamine Agonists; Ergolines; Ergot Alkaloids; Female; France; Humans; Lactation; Lisuride; Practice Patterns, Physicians'; Prolactin; Surveys and Questionnaires

2012